In vitro amyloid-β binding and inhibition of amyloid-β self-association by therapeutic albumin.
BACKGROUND
A promising approach for treating Alzheimer's disease relies on the net efflux of the amyloid-β (Aβ) peptide from the brain to peripheral plasma, as a result of plasma Aβ clearance promoted by plasma removal and therapeutic albumin replacement.


OBJECTIVE
To assess the binding of therapeutic albumin (Albutein, Grifols) to monomeric and aggregated Aβ according to methods previously tested on the interactions between Aβ and research-grade albumin.


METHODS
Albumin integrity and the interactions with albumin stabilizers (octanoic acid and N-Ac-Trp) were assessed through one-dimensional (1D) 1H-NMR and saturation transfer difference (STD) NMR spectra. The interactions between monomeric Aβ1-40 and albumin were probed by 2D 1H-15 N HSQC spectra of labeled Aβ1-40. The formation of cross-β structured Aβ1-42 assemblies was monitored by ThT fluorescence. The interactions between self-assembled Aβ1-42 and albumin were probed by Trp fluorescence.


RESULTS
NMR spectra indicated that both therapeutic and research-grade albumin are similarly well-folded proteins. No significant changes in either HSQC peak position or intensity were observed upon addition of albumin to 15N-labeled Aβ1-40, which rules out binding of albumin to monomeric Aβ with dissociation constant in the μM or lower range. When aggregated Aβ1-42 was added to albumin, quenching of Trp fluorescence was observed, which indicates albumin binding to Aβ1-42 aggregates. The relative potency of therapeutic albumin as an Aβ self-association inhibitor was in the same order of magnitude as research-grade albumin.


CONCLUSIONS
Albutein inhibited Aβ self-association by selectively binding Aβ aggregates rather than monomers and by preventing further growth of the Aβ assemblies.
Department of Chemistry and Chemical Biology, McMaster University, Hamilton, ON, Canada.
Julijana
J
Milojevic
Montserrat
M
Costa
Ana M
AM
Ortiz
Juan I
JI
Jorquera
Giuseppe
G
Melacini
D000544:Alzheimer Disease / Q000188:drug therapy / Q000378:metabolism; D016229:Amyloid beta-Peptides / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D006801:Humans; D019906:Nuclear Magnetic Resonance, Biomolecular / Q000379:methods; D010446:Peptide Fragments / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D011485:Protein Binding / Q000502:physiology; D012709:Serum Albumin / Q000378:metabolism* / Q000502:physiology / Q000627:therapeutic use*
D016229:Amyloid beta-Peptides; D010446:Peptide Fragments; D012709:Serum Albumin; C075222:amyloid beta-protein (1-42)
Alzheimer's disease; NMR; amyloid; amyloid-β peptide; oligomers; therapeutic albumin